Skip navigation

The Race Between Biotech And Techbio

By Niven R. Narain, Ph.D., President & CEO, BPGbio Inc. — Forbes Councils Member

April 15, 2024

In late 2023, trillion-dollar chipmaker and high-end graphics processing unit (GPU) manufacturer Nvidia joined forces with Recursion, one of the few AI biotech companies that have assets in Phase 2 or Phase 3 trials, to accelerate foundational models in biology and chemistry at an unprecedented scale in the biopharma space.

This collaboration, along with others, exemplifies the growing “techbio” industry, which leverages technology to expedite drug discovery. As Kimberly Powell, head of Nvidia’s healthcare segment, aptly shared in a Bloomberg report, data can “drive what biology they’re going after, instead of the biology influencing what technology they need to use,” emphasizing the synergy between the two fields.


Read more @ Forbes The Race Between Biotech And Techbio